IP Verse

Injectable Gels Comprising Cross-Linked Hyaluronic Acid And Hydroxyapatite, And Methods Of Manufacturing Thereof

Patent No. EP3509559 (titled "Injectable Gels Comprising Cross-Linked Hyaluronic Acid And Hydroxyapatite, And Methods Of Manufacturing Thereof") was filed by Allergan Pharmaceuticals on Sep 7, 2017. The application was issued on Jul 19, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
MERZ PHARMAMar 7, 2024WALLINGER RICKER SCHLOTTER TOSTMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3509559

ALLERGAN PHARMACEUTICALS
Application Number
EP17848293A
Filing Date
Sep 7, 2017
Status
Granted And Under Opposition
May 5, 2023
Publication Date
Jul 19, 2023
External Links
Slate, Register , Google Patents